ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens

The routine availability of high-depth virus sequence data would allow the sensitive detection of resistance-associated variants that can jeopardize HIV or hepatitis C virus (HCV) treatment. We introduce ve-SEQ, a high-throughput method for sequence-specific enrichment and characterization of whole-virus genomes at up to 20% divergence from a reference sequence and 1,000-fold greater sensitivity than direct sequencing. The extreme genetic diversity of HCV led us to implement an algorithm for the efficient design of panels of oligonucleotide probes to capture any sequence among a defined set of targets without detectable bias. ve-SEQ enables efficient detection and sequencing of any HCV genome, including mixtures and intra-host variants, in a single experiment, with greater tolerance of sequence diversity than standard amplification methods and greater sensitivity than metagenomic sequencing, features that are directly applicable to other pathogens or arbitrary groups of target organisms, allowing the combination of sensitive detection with sequencing in many settings.

[1]  O. Pybus,et al.  Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing , 2015, Journal of Clinical Microbiology.

[2]  K. Reddy,et al.  Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. , 2015, Journal of hepatology.

[3]  Jolyon Holdstock,et al.  Rapid Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates Directly from Clinical Samples , 2015, Journal of Clinical Microbiology.

[4]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[5]  John McNally,et al.  Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.

[6]  V. Miller,et al.  Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group , 2014, Clinical pharmacology and therapeutics.

[7]  C. Rice,et al.  Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.

[8]  Huldrych F. Günthard,et al.  Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection , 2012, PLoS pathogens.

[9]  Gabor T. Marth,et al.  MOSAIK: A Hash-Based Algorithm for Accurate Next-Generation Sequencing Short-Read Mapping , 2013, PloS one.

[10]  K. Nakayama,et al.  Use of Illumina Deep Sequencing Technology To Differentiate Hepatitis C Virus Variants , 2011, Journal of Clinical Microbiology.

[11]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[12]  F. Baldanti,et al.  Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients , 2012, Virology Journal.

[13]  O. Pybus,et al.  Full-Length Characterization of Hepatitis C Virus Subtype 3a Reveals Novel Hypervariable Regions under Positive Selection during Acute Infection , 2009, Journal of Virology.

[14]  S. Brisse,et al.  Evaluation of High-Throughput Sequencing for Identifying Known and Unknown Viruses in Biological Samples , 2011, Journal of Clinical Microbiology.

[15]  E. Leproust,et al.  Specific Capture and Whole-Genome Sequencing of Viruses from Clinical Samples , 2011, PloS one.

[16]  W. Lipkin,et al.  Virome Capture Sequencing Enables Sensitive Viral Diagnosis and Comprehensive Virome Analysis , 2015, mBio.

[17]  Elizabeth M. Ryan,et al.  De novo assembly of highly diverse viral populations , 2012, BMC Genomics.

[18]  Juliane C. Dohm,et al.  Substantial biases in ultra-short read data sets from high-throughput DNA sequencing , 2008, Nucleic acids research.

[19]  F. S. Domingues,et al.  Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients , 2009, Hepatology.

[20]  Florian Hahne,et al.  QuasR: quantification and annotation of short reads in R , 2015, Bioinform..

[21]  A. Flaxman,et al.  Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.

[22]  Daniel J. Wilson,et al.  A Modified RNA-Seq Approach for Whole Genome Sequencing of RNA Viruses from Faecal and Blood Samples , 2013, PLoS ONE.

[23]  Marcel Martin Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[24]  Kevin Galinsky,et al.  Hybrid selection for sequencing pathogen genomes from clinical samples , 2011, Genome Biology.

[25]  Tarjei S Mikkelsen,et al.  Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples , 2014, Genome Biology.

[26]  Michael D. Miller,et al.  Genotype- and Subtype-Independent Full-Genome Sequencing Assay for Hepatitis C Virus , 2015, Journal of Clinical Microbiology.

[27]  C. Sabin,et al.  British HIV Association guidelines for the routine investigation and monitoring of adult HIV‐1‐infected individuals 2011 , 2012, HIV medicine.

[28]  Xiao Yang,et al.  V-Phaser 2: variant inference for viral populations , 2013, BMC Genomics.

[29]  A. Hughes,et al.  Analysis of Hepatitis C Virus Intrahost Diversity across the Coding Region by Ultradeep Pyrosequencing , 2012, Journal of Virology.

[30]  Paolo Piazza,et al.  Improved workflows for high throughput library preparation using the transposome-based nextera system , 2013, BMC Biotechnology.

[31]  Nihar Shah,et al.  Review of direct-acting antiviral agents for the treatment of chronic hepatitis C , 2013, Expert opinion on investigational drugs.

[32]  H. Chu,et al.  Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease , 2007, Antimicrobial Agents and Chemotherapy.

[33]  Sanjeev Arora,et al.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[34]  E. Schiff,et al.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. , 2013, The New England journal of medicine.